Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

How the viruses turn a B-cell into a lymphoma

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

A B-cell will not divide or survive without permission. Two signals grant it: one from its antibody receptor, one from a helper T-cell through a molecule called CD40.

Epstein-Barr virus carries proteins that counterfeit both. The cell behaves as though it has been authorized, and nobody authorized anything.

Related pages: AIDS-related lymphoma

The bottom line

What we know
  • EBV proteins LMP1 and LMP2A mimic CD40 and B-cell receptor signalling.
  • This makes the cell survive and divide without genuine immune signals.
  • KSHV carries viral copies of cyclin D and interleukin-6.
  • Chromosomal translocations involving MYC, BCL6 and BCL2 complete the transformation.
What is still open
  • Why some EBV-infected B-cells transform and the vast majority never do.
  • Whether EBV-directed therapies can be made to work in these lymphomas.

The story, step by step

  1. 1. The permission system ()
  2. 2. LMP1 ()
  3. 3. Latency programs ()
  4. 4. KSHV ()
  5. 5. The genetic hit ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

What a B-cell needs to survive

Review of many studies

What happens

Understanding the fraud requires understanding the legitimate system first.

What the research shows

  • A B-cell that encounters its target gets a signal through its B-cell receptor, confirming the antibody works.
  • It then needs a second signal from a helper T-cell, delivered through a surface molecule called CD40, confirming the target is genuinely foreign.
  • Without both, the cell undergoes apoptosis. This is deliberate: it is how the body prevents antibodies against itself.
  • In the germinal centre, where B-cells rewrite their antibody genes, this checking is at its most stringent.
  • Most B-cells that enter a germinal centre die there, which is the system working correctly.

Why it matters

The B-cell system is built around killing almost everything, which is precisely the safeguard EBV defeats.

What's still uncertain

  • How the two signals are integrated inside the cell is still being mapped in detail.

Read more

Next: LMP1

Part 2 of 5

A CD40 receptor permanently switched on

Review of many studies

What happens

The EBV protein LMP1 is the clearest piece of molecular counterfeiting known in virology.

What the research shows

  • LMP1 sits in the cell membrane and recruits the same internal signalling machinery that CD40 uses.
  • Unlike CD40, it does not need a T-cell to activate it. It clusters and signals continuously by itself.
  • The result is permanent activation of NF-kB, a master switch that turns on survival and growth genes.
  • The cell receives an unending message that a helper T-cell has approved it, when no T-cell is involved at all.
  • A second protein, LMP2A, imitates a permanently engaged B-cell receptor, supplying the other missing signal.

Why it matters

Between them, LMP1 and LMP2A forge both signatures the cell requires. This is why EBV can keep a B-cell alive indefinitely.

What's still uncertain

  • Not all EBV-positive lymphomas express LMP1; the pattern of expressed viral genes differs between subtypes.

Read more

Next: Latency programs

Part 3 of 5

Hiding more or less, depending on the audience

Review of many studies

What happens

EBV expresses different sets of genes in different situations, and which set it chooses depends on how much immune surveillance there is.

What the research shows

  • In healthy people, EBV-infected memory B-cells express almost nothing, which makes them nearly invisible to T-cells. This is latency 0 and I.
  • Expressing more viral proteins drives proliferation but also makes the cell a target, so in an intact immune system those cells are killed.
  • In severe immunosuppression, cells expressing the full set of growth-driving proteins, latency III, survive because nothing is killing them.
  • Primary CNS lymphoma in advanced HIV is essentially always EBV-positive, and this is why: it occurs where surveillance has collapsed entirely.
  • Burkitt lymphoma, which occurs at higher CD4 counts, uses a more restricted program and relies more on the MYC translocation.

Why it matters

Which latency program a lymphoma uses tracks how much immune function remains, which is why subtypes map onto CD4 counts so consistently.

What's still uncertain

  • Latency programs were defined in cell lines and are less clean in human tumours.

Read more

Next: KSHV

Part 4 of 5

Stolen human genes, used against us

Review of many studies

What happens

Kaposi sarcoma-associated herpesvirus, HHV-8, took a different approach: it stole copies of human genes.

What the research shows

  • It carries a viral version of cyclin D, a protein that pushes cells through the division cycle. The viral copy is not subject to the normal brakes.
  • It carries a viral version of interleukin-6, a growth factor for B-cells, which it produces continuously.
  • It also carries proteins that block apoptosis and interfere with the tumour suppressor p53.
  • KSHV is found in essentially all cases of primary effusion lymphoma, and in a form of plasmablastic lymphoma arising in multicentric Castleman disease.
  • Both of those are rare, and both are among the hardest of these lymphomas to treat.

Why it matters

A virus carrying its own uncontrollable copies of human growth genes is an unusually direct mechanism of cancer.

What's still uncertain

  • KSHV-driven lymphomas are rare enough that treatment evidence is limited to small series.

Read more

Next: The genetic hit

Part 5 of 5

Translocations that finish the job

Review of many studies

What happens

Viral signals alone do not produce a lymphoma. A genetic accident is usually needed too.

What the research shows

  • MYC, moved next to an antibody gene promoter by a translocation, becomes permanently switched on. MYC drives cell growth and division, and this is the defining lesion of Burkitt lymphoma.
  • BCL6 abnormalities lock the cell in a germinal-centre state, where the mutation machinery stays switched on.
  • BCL2 translocations block apoptosis, so damaged cells are not cleared.
  • In diffuse large B-cell lymphoma the genetics are more varied, and testing for MYC, BCL2 and BCL6 rearrangements is routine because it affects treatment.
  • The combination is what matters: viral signals keep the cell alive long enough for the genetic accident to happen, and the accident makes the growth permanent.

Why it matters

This is why the tissue biopsy must be large enough for genetic testing. The specific rearrangements change the treatment plan.

What's still uncertain

  • The full genetic landscape of HIV-associated lymphomas is less well characterized than that of lymphomas in people without HIV.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.